The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China
Frontiers in Public Health · 15.04.2024 · 12
DOI: 10.3389/fpubh.2024.1333487 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 15.04.2024. Verfasst von Zhanjing Dai und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cost-Benefit Analysis, Carbazoles, Crizotinib. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Iruplinalkib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with efficacy in patients with ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC), which is independently developed by a Chinese pharmaceutical company. This study examined the cost-effectiveness of iruplinalkib versus alectinib in the Chinese healthcare setting.
Methods
A partitioned survival model was developed to project the economic and health outcomes. Efficacy was derived using unanchored matching-adjusted indirect comparison (MAIC). Cost and utility values were obtained from the literature and experts’ opinions. Deterministic and probabilistic sensitivity analyses (PSA) were carried out to evaluate the model’s robustness.
Results
Treatment with iruplinalkib versus alectinib resulted in a gain of 0.843 quality-adjusted life years (QALYs) with incremental costs of $20,493.27, resulting in an incremental cost-effectiveness ratio (ICER) of $24,313.95/QALY. Parameters related to relative efficacy and drug costs were the main drivers of the model outcomes. From the PSA, iruplinalkib had a 90% probability of being cost-effective at a willingness-to-pay threshold of $37,863.56/QALY.
Conclusion
Compared to alectinib, iruplinalkib is a cost-effective therapy for patients with ALK-positive crizotinib-resistant advanced NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Zitieren
APA
Dai, Z., Xu, J., Chang, F., Zhou, W., Ren, T., Qiu, J., Lu, Y., & Lu, Y. (2024). The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China. Frontiers in Public Health, 12. https://doi.org/10.3389/fpubh.2024.1333487
Vancouver
Dai Z, Xu J, Chang F, Zhou W, Ren T, Qiu J, et al. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China. Frontiers in Public Health. 2024;12. doi:10.3389/fpubh.2024.1333487
BibTeX
@article{Dai2024,
author = {Dai, Zhanjing and Xu, Jiayi and Chang, Feng and Zhou, Wanxin and Ren, Ting and Qiu, Jiaxin and Lu, Yun and Lu, Yuqiong},
title = {The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China},
journal = {Frontiers in Public Health},
year = {2024},
volume = {12},
doi = {10.3389/fpubh.2024.1333487}
}
EUVIMED